AriBio Progresses Novel Alzheimer's Contender Despite Mixed Phase II
But Will Benefits Be Enough?
Executive Summary
Korea's AriBio is poised to file for US Phase III trial approval this year for its novel Alzheimer's candidate and lead asset AR1001, which showed an improvement in cognitive function from baseline at Phase II. But will the benefits over existing therapies be enough to carve a position in the challenging field?
You may also be interested in...
Aducanumab Approval Decision Delayed: Could This Be Good News?
Even analysts who still doubt the FDA will approve the anti-amyloid antibody as the first disease-modifying Alzheimer’s treatment said aducanumab’s likelihood of approval has improved.
ARIBIO Counts On Multi-Modal Drug For Alzheimer's And Vascular Dementia
ARIBIO CEO tells Scrip how the South Korean biotech is aiming to develop a multi-modal drug for both Alzheimer’s disease and vascular dementia using its innovative platform technology, which can cut development periods and costs and better predict clinical trial success.
Could SillaJen Get Back On Track Via M2N's Acquisition?
SillaJen selects another Korean firm as its new owner as trading in its stock continues to be suspended following the probe into its former CEO. But it remains to be seen whether the acquisition can catalyze a business breakthrough and speed up clinical development for the oncolytic immunotherapeutic firm.